Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

被引：4

作者：

Gressens, Simon B. ^{[1
]}

Wiedemann, Aurelie ^{[2
,4
]}

Dechenaud, Marie ^{[2
]}

Dupuis, Jehan ^{[3
]}

Gallien, Sebastien ^{[1
,4
]}

Melica, Giovanna ^{[1
,4
]}

Haioun, Corinne ^{[3
,4
]}

Lemonnier, Francois ^{[3
,4
]}

Levy, Yves ^{[1
,2
]}

机构：

[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France

[2] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, Team 16,INSERM U955, Creteil, France

[3] Grp Hosp Univ Chenevier Mondor, Serv Unite Hemopathies Lymphoides, IAP HP, F-94010 Creteil, France

[4] Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France

来源：

VACCINE | 2023年 / 41卷 / 09期

关键词：

Third dose; COVID-19; Immunocompromised; Vaccine; T cell responses; Hematological malignancies; SARS-COV-2; IMMUNITY;

D O I：

10.1016/j.vaccine.2023.01.064

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vac-cine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 ther-apies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal. (c) 2023 Elsevier Ltd. All rights reserved.

引用

页码：1550 / 1553

页数：4

共 50 条

[21] Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine
Salvagno, Gian Luca
Henry, Brandon M.
Lippi, Giuseppe
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2021, 63 (11) : E829 - E829
[22] Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients
Attolico, Immacolata
Tarantini, Francesco
Carluccio, Paola
Schifone, Claudia Pia
Delia, Mario
Gagliardi, Vito Pier
Perrone, Tommasina
Gaudio, Francesco
Longo, Chiara
Giordano, Annamaria
Sgherza, Nicola
Curci, Paola
Rizzi, Rita
Ricco, Alessandra
Russo Rossi, Antonella
Albano, Francesco
Larocca, Angela Maria Vittoria
Vimercati, Luigi
Tafuri, Silvio
Musto, Pellegrino
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 928 - 931
[23] Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients
Attolico, Imma
Tarantini, Francesco
Carluccio, Paola
Schifone, Claudia
Delia, Mario
Gagliardi, Vito Pier
Perrone, Tommasina
Gaudio, Francesco
Longo, Chiara
Giordano, Annamaria
Sgherza, Nicola
Curci, Paola
Rizzi, Rita
Ricco, Alessandra
Rossi, Antonella Vita Russo
Albano, Francesco
Larocca, Angela Maria Vittoria
Vimercati, Luig
Tafuri, Silvio
Musto, Pellegrino
BLOOD, 2021, 138
[24] Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients
Sgherza, Nicola
Zucano, Stefania
Vitucci, Angelantonio
Palma, Antonio
Tarantini, Francesco
Campanale, Daniela
Vimercati, Luigi
Maria, Angela
Larocca, Vittoria
Visceglie, Domenico
Acquafredda, Amalia
Ostuni, Angelo
Di Gennaro, Daniela
Vitucci, Carmen
Tafuri, Silvio
Musto, Pellegrino
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
[25] Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
Miele, Monica
Busa, Rosalia
Russelli, Giovanna
Sorrentino, Maria Concetta
Di Bella, Mariangela
Timoneri, Francesca
Mularoni, Alessandra
Panarello, Giovanna
Vitulo, Patrizio
Conaldi, Pier Giulio
Bulati, Matteo
AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (08) : 2919 - 2921
[26] Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy
Kastritis, Efstathios
Terpos, Evangelos
Evangelakou, Zoi
Theodorakakou, Foteini
Fotiou, Despina
Manola, Maria S.
Gianniou, Despoina D.
Bagratuni, Tina
Kanellias, Nikolaos
Migkou, Magdalini
Gavriatopoulou, Maria
Trougakos, Ioannis P.
Dimopoulos, Meletios A.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (01) : E27 - E31
[27] Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant
Stumpf, Julian
Tonnus, Wulf
Paliege, Alexander
Rettig, Ronny
Steglich, Anne
Gembardt, Florian
Kessel, Friederike
Kroger, Hannah
Arndt, Patrick
Sradnick, Jan
Frank, Kerstin
Tonn, Torsten
Hugo, Christian
TRANSPLANTATION, 2021, 105 (11) : E267 - E269
[28] Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR TCells Therapy
Gastinne, Thomas
Le Bourgeois, Amandine
Coste-Burel, Marianne
Guillaume, Thierry
Peterlin, Pierre
Garnier, Alice
Imbert, Berthe-Marie
Drumel, Thomas
Mahe, Beatrice
Dubruille, Viviane
Blin, Nicolas
Lok, Anne
Touzeau, Cyrille
Tessoulin, Benoit
Jullien, Maxime
Vantyghem, Sophie
Bene, Marie C.
Moreau, Philippe
Le Gouill, Steven
Chevallier, Patrice
BLOOD, 2021, 138
[29] The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
Saiag, Esther
Grupper, Ayelet
Avivi, Irit
Elkayam, Ori
Ram, Ron
Herishanu, Yair
Cohen, Yael
Perry, Chava
Furer, Victoria
Katchman, Helena
Rabinowich, Liane
Ben-Yehoyada, Merav
Halperin, Tami
Baruch, Roni
Goldshmidt, Hanoch
Hagin, David
Ben-Ami, Ronen
Sprecher, Eli
Bomze, David
CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (05) : 735.e5 - 735.e8
[30] Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
Li, Tingting
Gandra, Sumanth
Reske, Kimberly A.
Olsen, Margaret A.
Bommarito, Silvana
Miller, Candace
Hock, Karl G.
Ballman, Claire A.
Su, Christina
Le Dang, Na
Kwon, Jennie H.
Warren, David K.
Fraser, Victoria J.
Farnsworth, Christopher W.
ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2022, 2 (01):

← 1 2 3 4 5 →